Clinical implications of mutation analysis in primary hyperoxaluria type 1

Area of Science:

• Genetics
• Metabolic Disorders
• Nephrology

Background:

• Primary hyperoxaluria type 1 (PH1) is a genetic disorder of glyoxylate metabolism.
• PH1 exhibits significant clinical and genetic variability, complicating genotype-phenotype correlations.
• Understanding these correlations is crucial for improving patient care and management strategies.

Purpose of the Study:

• To investigate the association between specific AGXT gene mutations and clinical outcomes in PH1 patients.
• To identify genotype-specific predictors of disease severity and treatment response.
• To inform clinical management and genetic counseling for PH1.

Main Methods:

• Analysis of AGXT gene mutations in a Dutch cohort of 57 PH1 patients.
• Assessment of biochemical markers, clinical presentation, and treatment response.
• Correlation of identified mutations with patient outcomes, including renal function and disease progression.

Main Results:

• Ten distinct AGXT mutations were identified in 33 analyzed PH1 patients.
• Gly170Arg (43% allele frequency) and Phe152Ile (19%) mutations were linked to pyridoxine responsiveness and preserved renal function with timely treatment.
• Homozygous 33insC mutation (15%) was associated with end-stage renal disease (ESRD) before age one, leading to early mortality in 2/3 cases.
• Novel mutations Val336Asp and Gly82Arg were also identified, with Gly82Arg showing adverse outcomes in some patients.

Conclusions:

• Early detection of Gly170Arg and Phe152Ile mutations is clinically significant due to their association with pyridoxine responsiveness and better renal outcomes.
• The severe infantile ESRD linked to homozygous 33insC mutations highlights the importance of prenatal diagnostics for affected families.
• Genotype-guided management and early intervention are critical for optimizing outcomes in PH1.